Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 129, Issue 6, pp 592–594 | Cite as

Effects of synthetic bis-β-chloroethylamine estrogen derivatives on proliferation of skin sarcoma cells

  • A. V. Semeikin
  • V. M. Rzheznikov
  • E. E. Mayatskaya
  • Z. S. Smirnova
Oncology

Abstract

The effects of four new synthetic bis-β-chloroethylamine-containing estrogens and known cytostatic agents chlorophenacyl and estradiol mustard were compared on monolayer cultures of transformed L-929 fibroblasts (from murine skin sarcoma). The drugs within the concentration range of 10−5-5×10−7M inhibited proliferation of cultured cells by 67%. Chlorophenacyl displayed the least antiproliferative activity (15% inhibition at 10−5M). Steroid nucleus introduced into the molecule enhanced antiproliferative activity of test drug in comparison with chlorophenacyl, probably due to accumulation of the hormone-cytostatic molecules in cells. Estradiol had no effect on proliferative activity of L-929 cells, and no specific estrogen-binding sites were found in cultured transformed fibroblasts. The antiproliferative effect of hormone-cytostatics on this culture is not mediated via specific interactions with estrogen receptors.

Key Words

cytostatic estrogens cell culture transformed fibroblasts 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. S. Bassalyk, V. V. Kuz'mina, and N. I. Murav'eva,Receptors for Steroid Hormones in Human Tumors [in Russian], Moscow (1987).Google Scholar
  2. 2.
    Animal Cell Cultures: Methods [in Russian], Ed. R. Freshni, Moscow (1989).Google Scholar
  3. 3.
    E. N. Shkodinskaya, in:Problems of Experimental and Clinical Oncology [in Russian] (1972), pp. 64–71.Google Scholar
  4. 4.
    R. B. Everson, R. W. Turnell, J. L. Wittliff, and T. C. Hall,Cancer Chemother. Rep.,58, 353–357 (1974).PubMedGoogle Scholar
  5. 5.
    B. Fredholm, G. Jensen, M. Lindskog, and J. Muntzing,Acta Pharmacol. Toxicol.,35, 28–32 (1993).Google Scholar
  6. 6.
    J. Muntzing, G. Jensen, and B. Hogberg,Acta Pharmacol. Toxicol.,44, 1–6 (1994).CrossRefGoogle Scholar
  7. 7.
    K. Pavelic, I. Zgradic, and K. Pavelic,J. Cancer Res. Clin. Oncol.,117, 244–248 (1991).PubMedCrossRefGoogle Scholar
  8. 8.
    K. Pavelic, I. Zgradic, M. Osmak, and M. Popovic,Res. Exp. Med.,185, 233–243 (1985).CrossRefGoogle Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 2000

Authors and Affiliations

  • A. V. Semeikin
    • 1
    • 2
  • V. M. Rzheznikov
    • 1
    • 2
  • E. E. Mayatskaya
    • 1
    • 2
  • Z. S. Smirnova
    • 1
    • 2
  1. 1.Department of Molecular Pharmacology and RadiobiologyRussian State Medical UniversityMoscow
  2. 2.Endocrinological Research CenterRussian Academy of Medical SciencesMoscow

Personalised recommendations